Drug Trial Radar · NCT03549871
A Study of Fitusiran in Severe Hemophilia A and B Patients Previously Receiving Factor or Bypassing Agent Prophylaxis
Last checked: Nov 19, 2026Latest source record: Feb 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
80
Actual
Start
Jul 25, 2018
Primary completion
Jan 20, 2022
Study completion Mar 25, 2022
Sponsor
- Lead sponsor
- Genzyme, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Jun 8, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Objective: To characterize the frequency of bleeding episodes (BE) while receiving fitusiran treatment, relative to the frequency of bleeding episodes while receiving factor concentrate or bypassing agent (BPA) prophylaxis. Secondary Objectives: * To characterize the following while receiving fitusiran treatment, relative to receiving factor or BPA prophylaxis: * the frequency of spontaneous bleeding episodes * the frequency of joint bleeding episodes * health related quality of life (HRQOL) in participants greater than or equal to (\>=) 17 years of age * To characterize the frequency of bleeding episodes during the onset and treatment periods in participants receiving fitusiran. * To characterize the safety and tolerability of fitusiran. * To characterize the annualized weight-adjusted consumption of factor/BPA while receiving fitusiran treatment, relative to receiving factor or BPA prophylaxis.
Conditions
- Hemophilia
Interventions
FitusiranDrug
Pharmaceutical form: solution for injection Route of administration: subcutaneous
BPA prophylaxisDrug
Pharmaceutical form: solution for injection Route of administration: Intravenous
Factor (FVIII or FIX) prophylaxisDrug
Pharmaceutical form: solution for injection Route of administration: Intravenous
Primary outcomes
What the sponsor says the trial is designed to measure.
- Estimated Annualized Bleeding Rate (ABR)Time frame: Factor/BPA prophylaxis period: Day -168 to Day -1 or up to last day of bleeding follow up (any day up to Day -1); 6-month fitusiran efficacy period: Day 29 to Day 190 or up to last day of bleeding follow up (any day up to Day 190), whichever was earliest
- Observed Annualized Bleeding Rate (ABR)Time frame: Factor/BPA prophylaxis period: Day -168 to Day -1 or up to last day of bleeding follow up (any day up to Day -1); 6-month fitusiran efficacy period: Day 29 to Day 190 or up to last day of bleeding follow up (any day up to Day 190), whichever was earliest
Locations
35 sites in 15 countries. Site status is shown where the registry gives one.
Investigational Site Number 0139
Los Angeles, California
Investigational Site Number 6104
Prahran, Australia
Investigational Site Number 8604
Beijing, China
Investigational Site Number 4501
Copenhagen, Denmark
Investigational Site Number 3303
Lyon, France
Investigational Site Number 5301
Crumlin, Ireland
Investigational Site Number 9701
Ramat Gan, Israel
Investigational Site Number 3902
Milan, Italy
Investigational Site Number 8101
Nagoya, Japan
Investigational Site Number 8102
Nishinomiya, Japan
Investigational Site Number 8104
Saitama, Japan
Investigational Site Number 8109
Tokyo, Japan
Investigational Site Number 6004
Ampang, Malaysia
Investigational Site Number 6002
Johor Bahru, Malaysia
Investigational Site Number 6003
Kota Kinabalu, Malaysia
Investigational Site Number 5201
San Pablo, Mexico
Investigational Site Number 8201
Busan, South Korea
Investigational Site Number 8202
Daejeon, South Korea
Investigational Site Number 8204
Seoul, South Korea
Investigational Site Number 9002
Adana, Turkey (Türkiye)
Investigational Site Number 9001
Ankara, Turkey (Türkiye)
Investigational Site Number 9004
Antalya, Turkey (Türkiye)
Investigational Site Number 9008
Gaziantep, Turkey (Türkiye)
Investigational Site Number 9005
Istanbul, Turkey (Türkiye)
Investigational Site Number 9010
Izmir, Turkey (Türkiye)
Investigational Site Number 9003
Izmir, Turkey (Türkiye)
Investigational Site Number 9009
Kayseri, Turkey (Türkiye)
Investigational Site Number 9006
Samsun, Turkey (Türkiye)
Investigational site number 9013
Van, Turkey (Türkiye)
Investigational Site Number 8003
Kyiv, Ukraine
Investigational Site Number 8002
Lviv, Ukraine
Investigational Site Number 4402
Glasgow, United Kingdom
Investigational Site Number 4407
London, United Kingdom
Investigational Site Number 4403
London, United Kingdom
Investigational Site Number 4401
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.